Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxprenolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 12/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.72 |
| ▸ | HTR2B | P41595 | 4/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxprenolol SCHEMBL29698472 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL29698462 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL17464297 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL16310 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL6508035 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL30209192 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL29935146 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL123517 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL628369 | 0.97 | ADRB2 (0.95) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 | |
| Oxprenolol SCHEMBL11334535 | 0.89 | ADRB2 (0.78) | ADRB2ADRB1CYP2D6CYP1A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14102 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260000769-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-01-01 | — | — | US | claimed |
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| US-20250352510-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-11-20 | — | — | US | claimed |
| US-20250345461-A1 | METHOD FOR REPAIRING HAIR CYCLE-RELATED GENES AND METHOD FOR TREATING HAIR CYCLE-RELATED DISEASES USING MIR-520D-5P | LIVIUS PTE LTD (SG) | 2025-11-13 | — | — | US | claimed |
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| US-20250325671-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2025-10-23 | — | — | US | claimed |
| US-4428883-A | NASAL OINTMENTS OR GELS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-01-31 | — | — | US | claimed |
| EP-0073819-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1983-03-16 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| WO-1982003009-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | UNIV KENTUCKY RES FOUND (US) | 1982-09-16 | — | — | WO | claimed |
| US-4327725-A | Osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | claimed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |